Acasti Pharma Inc. (ACST)
- Previous Close
2.5600 - Open
2.6094 - Bid --
- Ask --
- Day's Range
2.5901 - 3.0900 - 52 Week Range
1.9800 - 3.5900 - Volume
160,523 - Avg. Volume
16,188 - Market Cap (intraday)
31.028M - Beta (5Y Monthly) 1.51
- PE Ratio (TTM)
-- - EPS (TTM)
-1.4300 - Earnings Date Nov 11, 2024 - Nov 15, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
6.08
Acasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal betamethasone spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was incorporated in 2002 and is headquartered in Princeton, New Jersey.
www.acastipharma.comRecent News: ACST
View MorePerformance Overview: ACST
Trailing total returns as of 9/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ACST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ACST
View MoreValuation Measures
Market Cap
26.26M
Enterprise Value
3.26M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.44
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-11.62%
Return on Equity (ttm)
-18.56%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-11.45M
Diluted EPS (ttm)
-1.4300
Balance Sheet and Cash Flow
Total Cash (mrq)
19.41M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-5.58M